Company: PFSA
Filing Date: 2025-05-15
Form Type: 424B3
Source: 0001213900-25-044417
Chunk: 314

Company: Profusa, Inc.
Filing Date: 2025-05-15
Form: 424B3
Chunk 314
---
 limited to, the following: redemptions, complexities related to the stockholder vote, litigation and threats of litigation and broader macroeconomic risks, including Profusa’s status as an early stage company without an operating history, the competitive landscape, the uncertainties of FDA approval and the execution risk that could create difficulties for Profusa in effectively managing its commercialization and distribution of its products and, subsequently, managing its growth and expanding its operations. Specifically, the NorthView Board considered the following issues and risks: • Risk that the benefits described above may not be achieved.The risk that the potential benefits of the Merger may not be fully achieved, or may not be achieved within the expected timeframe. • Risk of the liquidation of NorthView.The risks and costs to NorthView if the Merger is not completed, including the risk of diverting management’s focus and resources from other business combination opportunities, which could result in NorthView being unable to effect a business combination in the requisite time frame and force NorthView to liquidate. • Exclusivity.The fact that the Merger Agreement includes an exclusivity provision that prohibits NorthView from soliciting other business combination proposals, which restricts NorthView’s ability, so long as the Merger Agreement is in effect, to consider other potential business combinations. • Risks regarding the stockholder vote.The risk that NorthView’s stockholders may fail to provide the votes necessary to effect the Merger. • Closing conditions.The fact that completion of the Merger is conditioned on the satisfaction of certain closing conditions that are not within NorthView’s control, including approval by NorthView’s stockholders and approval by Nasdaq of the initial listing application in connection with the Merger. • Potential litigation.The possibility of litigation challenging the Merger or that an adverse judgment granting permanent injunctive relief could indefinitely enjoin consummation of the Merger. • Fees and expenses.The fees and expenses associated with completing the Merger. • Potential impacts of COVID -19 .Uncertainties regarding the potential impacts of the COVID -19virus and related economic disruptions on Profusa’s operations. • Other risk factors.Various other risk factors associated with the respective businesses of NorthView and Profusa as described in the section entitled “ Risk Factors” appearing elsewhere in this proxy statement/prospectus. We may complete the Business Combination only if it is approved by the affirmative vote of the members representing at least a simple majority of the votes cast by holders of NorthView Common Stock present and voting in person or by proxy at the special meeting of NorthView